These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14531918)

  • 1. Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy.
    Dargaud Y; Trzeciak MC; Meunier S; Angei C; Pellechia D; Négrier C; Vinciguerra C
    Br J Haematol; 2003 Oct; 123(2):342-5. PubMed ID: 14531918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF; Lensen RP; Bertina RM
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of factor V Leiden mutation and prothrombin 20210A variant in Romanies of Eastern Hungary.
    Balogh I; Póka R; Losonczy G; Muszbek L
    Thromb Haemost; 1999 Nov; 82(5):1555-6. PubMed ID: 10595655
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
    Mikovic D; Rakicevic L; Kovac M; Radojkovic D
    Thromb Haemost; 2000 Oct; 84(4):723-4. PubMed ID: 11057877
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden.
    Murphy CH; Sabath DE
    Am J Clin Pathol; 2019 Feb; 151(3):302-305. PubMed ID: 30423028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [APC resistance--most frequent familial thrombophilia].
    Herren S; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):499-501. PubMed ID: 10517118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
    Tosetto A; Castaman G; Cappellari A; Rodeghiero F
    Thromb Haemost; 2000 Nov; 84(5):811-4. PubMed ID: 11127861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family.
    Santamaría A; Soria JM; Tirado I; Mateo J; Coll I; Souto JC; Fontcuberta J
    Thromb Haemost; 2005 Jun; 93(6):1193-5. PubMed ID: 15968408
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
    Rolla R; Vidali M; Meola S; Pollarolo P; Pergolini P; Bellomo G
    Clin Lab; 2011; 57(9-10):711-7. PubMed ID: 22029186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C resistance assay and factor V Leiden.
    Prüller F; Weiss EC; Raggam RB; Cervar-Zivkovic M; Renner W; Wagner J; Michaelis S; März W; Mangge H
    N Engl J Med; 2014 Aug; 371(7):685-6. PubMed ID: 25119624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation.
    de Ronde H; Bertina RM
    Blood Coagul Fibrinolysis; 1999 Jan; 10(1):7-17. PubMed ID: 10070830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R; Quehenberger P; Wu JR; Wilmer M
    Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.
    Perez Botero J; Majerus JA; Strege AK; Johnson RD; Chen D; Pruthi RK
    Am J Clin Pathol; 2017 Jun; 147(6):604-610. PubMed ID: 28472350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombophilia as a multigenic disease.
    Zöller B; García de Frutos P; Hillarp A; Dahlbäck B
    Haematologica; 1999 Jan; 84(1):59-70. PubMed ID: 10091393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The concomitant presence of prohemorrhagic and thrombophilic changes in coagulation factor V: a severe defect of coagulant activity and homozygote resistance to activated protein C].
    Rossi V; Di Rocco N; Del Sonno C; Crivelli S
    Ann Ital Med Int; 1999; 14(2):127-9. PubMed ID: 10399376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia.
    Houghton DE; Sud S; Moll S; Rollins-Raval MA
    Vasc Med; 2017 Dec; 22(6):527-528. PubMed ID: 28965480
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F5 R506Q (factor V Leiden) mutation.
    Prüller F; Raggam RB; Mangge H; Truschnig-Wilders M; Matzhold EM; Weiss EC; Hasiba B; Summers KL; Renner W; Siegert G; Kostka H
    Br J Haematol; 2013 Nov; 163(3):414-7. PubMed ID: 23957718
    [No Abstract]   [Full Text] [Related]  

  • 19. No association between thrombosis and factor V gene polymorphisms in Chinese Han population.
    Yanqing H; Fangping C; Qinzhi X; Zaifu J; Guangping W; Xiaoxia Z; Xiaoqun P; Xiaobo
    Thromb Haemost; 2003 Mar; 89(3):446-51. PubMed ID: 12624626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In the presence of other inherited or acquired high-risk situations, the FV Cambridge mutation may be an additional thrombophilic risk factor, through its effect on APC sensitivity.
    Santacroce R; Bossone A; Brancaccio V; Fortina P; Margaglione M
    Thromb Haemost; 2000 Jun; 83(6):963-4. PubMed ID: 10896257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.